SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes

Kenta Nonomura; Katsumi Iizuka; Yayoi Kuwabara-Ohmura; Daisuke Yabe

doi:10.2169/internalmedicine.4323-19

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes

Kenta Nonomura, Katsumi Iizuka, Yayoi Kuwabara-Ohmura, Daisuke Yabe

著者情報

キーワード: diabetic kidney disease, estimated glomerular filtration rate, type 2 diabetes mellitus, GLP-1 receptor agonist, SGLT2 inhibitor

ジャーナルオープンアクセス早期公開

論文ID: 4323-19

DOI https://doi.org/10.2169/internalmedicine.4323-19

この記事には本公開記事があります。

The final version of this article is now available: Vol. 59 (2020), No. 12 pp. 1535-1539

詳細

抄録

A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 ml/min/1.73 m². A renal biopsy revealed diabetic nephropathy. sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）